Latest Breaking News On - Jon stonehouse - Page 1 : comparemela.com

BioCryst Pharmaceuticals, Inc : BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

BioCryst Pharmaceuticals, Inc : BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesHelen thackrayJohn bluthCharlie gayerJon stonehouseBiocryst pharmaceuticals incInternational society for pharmacoeconomicsBiocryst pharmaceuticalsOutcomes researchExchange commissionCryst pharmaceuticalsOnce daily treatmentHereditary angioedemaAnnual reportQuarterly reportsCurrent reports

BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript

BCRX earnings call for the period ending March 31, 2024.

United statesAnthony doyleHelen thackrayTazeen ahmadMaury raycroft jefferiesGena wang barclaysFrancois briseboisJon stonehouseCharlie gayerBrian abrams abrahamsAmerica merrill lynchChris raymond piper sandlerLiisa bayko evercoreJessica fyeLiisa baykoJon wolleben

Why Is BioCryst Stock Trading Higher On Monday? - BioCryst Pharma (NASDAQ:BCRX)

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue

United statesBiocryst pharmaJon stonehouseBiocryst pharmaceuticals incBiocryst pharmaceuticalsCryst pharma

BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2023.

United statesDiscovery centerMaury raycroftCharlie gayerFrancois briseboisJessica fyeLiisa bayko evercoreBryan arnoldGena wang barclaysTazeen ahmadSerge belangerMaury raycroft jefferiesJon stonehouseAmerica merrill lynchFrancois brisebois oppenheimerSerge belanger needham

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoJohn bluthJon stonehouseCharlie gayerBiocryst pharmaceuticalsDiscovery centerBiocryst pharmaceuticals incExchange commissionCryst pharmaceuticalsFourth quarterFull yearInflation reduction actProfitability outlooktheHealthcare conferenceon tuesdayHealthcare conference